DORAs: Why the Newest Class of Sleep Meds May Actually Be Good for You
If you've ever been prescribed a sleep medication, there's a good chance it was something like zolpidem (Ambien), a benzodiazepine, or one of their close cousins. Or you take an over the counter antihistamine hoping for rest. These drugs work — in the short term. But they come with a well-documented set of tradeoffs: tolerance, cognitive impairment, fall risk, disrupted sleep architecture, and the miserable experience of rebound insomnia when you try to stop.
For decades, that was more or less the deal. You could sleep with medication, or you could struggle without it.
A newer class of sleep medication — dual orexin receptor antagonists, or DORAs — has fundamentally changed that calculus. And the more the science matures, the more these drugs look not just safer than their predecessors, but potentially beneficial in ways that go beyond simply getting you to sleep.
How Traditional Sleep Medications Work (and Why That's a Problem)
Benzodiazepines and Z-drugs like zolpidem work by amplifying the activity of GABA, the brain's main inhibitory neurotransmitter. Think of GABA as a broad dimmer switch for the nervous system: turn it up, and the brain slows down — including functions you'd prefer to leave intact, like memory consolidation, respiratory drive, muscle tone, and normal sleep architecture.
This is why these medications carry such a long list of concerns. In older adults, the muscle-relaxant effects of GABAergic drugs dramatically increase fall and fracture risk. In patients with sleep apnea or lung disease, they can blunt the respiratory drive. With regular use, the brain adapts — meaning you need more drug to get the same effect, and stopping the medication can trigger a rebound worse than the original insomnia. Long-term benzodiazepine use has been associated with cognitive decline, particularly in older populations.
Perhaps most importantly, GABAergic drugs distort sleep architecture. They tend to suppress REM sleep — the phase associated with emotional regulation, memory consolidation, and cognitive restoration — and alter the proportions of deep sleep stages in ways that may undermine the very restorativeness of the sleep they're inducing.
You're sedated, but you're not sleeping the way your brain was designed to sleep.
DORAs: A Fundamentally Different Approach
Dual orexin receptor antagonists work from an entirely different direction. Rather than pushing the brain toward sedation, they quiet the signal that keeps you awake.
Orexin is a neuropeptide produced in the hypothalamus that functions as the brain's primary wakefulness promoter. It acts on two receptors — OX1R and OX2R — to maintain arousal, stabilize the sleep-wake cycle, and suppress sleep during waking hours. In people with insomnia, this system is often overactive: the brain's "stay awake" signal is too loud, even when the body is exhausted.
DORAs block both orexin receptors, selectively reducing that wake-promoting drive. As one sleep medicine specialist summarized it: “rather than increasing sedation, DORAs reduce wakefulness — attacking insomnia from the opposite direction.” The result is sleep that arises more naturally, because the obstacle to sleep is removed rather than the brain being chemically bludgeoned into unconsciousness.
There are currently three FDA-approved DORAs in the United States: suvorexant (Belsomra), lemborexant (Dayvigo), and daridorexant (Quviviq), approved in 2014, 2019, and 2022 respectively. A fourth, vornorexant, was approved in Japan in 2025 and may reach U.S. markets.
The Safety Advantages Are Real
The clinical differences between DORAs and traditional sleep aids are not subtle.
Falls and fractures: One of the most serious risks of traditional sleep medications, especially in older adults, is the increased likelihood of nighttime falls. Because DORAs don't act on GABA receptors, they don't cause the muscle relaxation that makes falling dangerous. A 2024 meta-analysis of over 46,000 patients found that DORAs did not increase the risk of falls or fractures — a striking contrast to benzodiazepines and Z-drugs.
Respiratory safety: Traditional hypnotics suppress the respiratory drive, making them dangerous in patients with obstructive sleep apnea, COPD, or those taking opioid pain medications. DORAs do not affect respiratory drive, making them a meaningfully safer option for patients with these conditions.
Dependency and tolerance: Post-marketing surveillance data on DORAs shows low abuse potential and no evidence of meaningful physical dependence. Clinical trials have also found no evidence of tolerance developing over time — the drug continues to work at the same dose. Discontinuing a DORA does not appear to cause the rebound insomnia that makes stopping benzodiazepines and Z-drugs so difficult.
Next-day function: Because DORAs target the wake-promoting system rather than broadly suppressing the central nervous system, they produce fewer next-day residual effects — less grogginess, less cognitive impairment, less motor interference than traditional sedative-hypnotics.
In a systematic review ranking 20 insomnia medications, DORAs ranked highest on key efficacy measures — sleep latency, wake time after sleep onset, total sleep time, and sleep efficiency — while achieving the second-best safety profile of all agents evaluated, behind only placebo.
The Sleep Architecture Story: Where It Gets Interesting
Here is where DORAs depart most meaningfully from their predecessors, and where the science is generating some exciting questions.
Traditional sleep medications suppress REM sleep — the phase during which the brain processes emotions, consolidates memories, and clears metabolic waste. Chronic REM suppression is not benign. It's associated with daytime cognitive dysfunction, mood dysregulation, and over time, a kind of sleep debt that no amount of drug-induced unconsciousness can repay.
DORAs do the opposite. Studies consistently show that DORAs increase total sleep time primarily by promoting REM sleep, without suppressing — and sometimes even increasing — natural sleep architecture. They appear to produce sleep that more closely resembles the brain's own natural sleep pattern, with EEG profiles during DORA-induced sleep that are difficult to distinguish from unmedicated sleep.
This distinction matters for several reasons, including one that has attracted significant research attention: the relationship between sleep, the orexin system, and neurodegeneration.
A Potential Role in Brain Health
One of the most compelling emerging areas in sleep research concerns the brain's glymphatic system — a waste-clearance network that operates primarily during sleep, flushing out metabolic byproducts including amyloid-beta and tau proteins, the pathological hallmarks of Alzheimer's disease. Poor sleep, and particularly disrupted REM sleep, impairs this clearance process.
Research has found that patients with Alzheimer's disease tend to have elevated orexin levels in their cerebrospinal fluid, and that these elevated levels correlate with reduced REM sleep and accelerated cognitive decline. Animal studies have shown that suvorexant reduced amyloid accumulation in the brain and improved cognitive performance in Alzheimer's mouse models. Suvorexant is now FDA-approved for sleep disturbances in mild to moderate Alzheimer's dementia, and notably, it does so without worsening the underlying cognitive impairment — something most traditional hypnotics cannot claim.
Researchers are now exploring whether DORAs, by improving sleep quality and promoting REM sleep, may have a role not just in treating insomnia but in mitigating the risk of neurodegenerative disease progression. This is still an active area of research, not a proven clinical application — but it represents a genuine paradigm shift in how we think about sleep medications. The idea that a sleep drug might not merely be a necessary evil, but an intervention that could support long-term brain health, would have been difficult to take seriously even ten years ago.
Who Are DORAs Right For?
DORAs are appropriate for adults with insomnia characterized by difficulty falling asleep, staying asleep, or both. They are a particularly strong option for:
Older adults, in whom the fall risk and cognitive effects of traditional hypnotics are most dangerous
Patients with sleep apnea or lung disease, who cannot safely use respiratory-suppressing medications
Patients taking opioids, in whom GABAergic drugs compound the respiratory risk
Patients with comorbid anxiety or mood disorders, where orexin system dysregulation may contribute to both sleep and emotional symptoms
Anyone concerned about dependency or long-term cognitive effects of traditional sleep aids
The main practical limitation of DORAs is cost. Without insurance coverage, they are significantly more expensive than generic zolpidem or benzodiazepines. Coverage has improved as these drugs have become more established, and some manufacturers offer assistance programs, but this remains a consideration worth discussing with your physician.
It's also worth noting that pharmacological therapy — DORA or otherwise — is generally considered a complement to, not a substitute for, cognitive behavioral therapy for insomnia (CBT-I), which remains the first-line treatment for chronic insomnia and has durable benefits that medication alone does not provide (see my prior article on sleep).
The Bottom Line
The old model of sleep medication was largely about sedation — turning down the brain until sleep occurred, with all the collateral damage that entailed. The DORA model is something different: a targeted intervention that quiets the specific signal keeping you awake, allowing sleep to emerge more naturally, preserving the architecture of restorative sleep, and avoiding the dependency, cognitive, and safety risks of the drugs they're replacing.
For patients who need pharmacological help with sleep, DORAs represent a genuine advance. And the emerging evidence around sleep quality, brain clearance, and neurodegeneration suggests the implications of getting sleep right may be far broader than most of us have appreciated.
There are still certainly roles for the hypnotics and benzodiazepines, but DORAs offer a host of advantages.
